Endocrine determinants of MASLD: mechanisms and therapeutic targets.
9 affiliations
- 1Advance Centre for Obesity, Diabetes and Endocrinology (ACODE), Indraprastha Apollo Hospital, Delhi, India.
- 2Department of Endocrinology, Fortis Hospital, Gurugram, Haryana, India.
- 3Department of Endocrinology, Max Superspecialty Hospital, Dwarka, Delhi, India.
- 4Department of Endocrinology, Yatharth Super Speciality Hospital, New Delhi, India.
- 5Department of Endocrinology, Aakash Hospital, Dwarka, Delhi, India.
- 6Department of Endocrinology, Fortis Escorts Heart Institute, Delhi, India.
- 7Department of Endocrinology, Max Super Speciality Hospital, Ghaziabad, Uttar Pradesh, India.
- 8Division of Cardiovascular Medicine, UC Davis Medical Center, Sacramento, CA, United States.
- 9Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, Redwood, CA, United States.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 30% of adults worldwide, yet is still framed largely as a hepatological disorder despite being driven substantially by endocrine and metabolic dysfunction. This review proposes a unified endocrine framework organised around seven hormonal axes, presenting each in terms of molecular pathogenesis, clinical presentation, and therapeutic implications. Insulin resistance is the central driver, coupling chronic caloric excess to hepatic de novo lipogenesis through selective hepatic insulin resistance, although genetic variants in PNPLA3 and TM6SF2 can uncouple steatosis from metabolic risk. Adipose tissue dysfunction contributes through adipocyte senescence, adipokine imbalance, and inflammatory adipose-liver signalling. Reduced hepatic thyroid hormone sensitivity, even in euthyroid individuals, predicts steatosis and fibrosis and underpins the first approved liver-directed therapy. Gonadal steroids exert sexually dimorphic effects, with testosterone deficiency, menopausal oestrogen loss, and polycystic ovary syndrome representing distinct risk states. Glucocorticoid dysregulation is stage-dependent, shifting from enhanced hepatic cortisol clearance in steatosis to local amplification in steatohepatitis. The gut-liver-endocrine axis, encompassing incretin, bile acid, and fibroblast growth factor signalling, has proved the most therapeutically tractable. Reduced GH/IGF-1 signalling, whether from pituitary disease or obesity-induced functional suppression, promotes both steatosis and fibrogenesis. Biological sex and life-course influences spanning developmental programming and ageing further modify these determinants. Two agents, resmetirom and semaglutide, now have US FDA accelerated approval for noncirrhotic MASH with moderate-to-advanced fibrosis, supporting the principle that correcting axis-specific endocrine dysfunction can produce measurable hepatic benefit; however, both approvals are accelerated and await confirmatory outcome data, while others remain investigational. An endocrine framework offers both a coherent account of pathogenesis and a rational basis for biomarker-guided, phenotype-targeted therapy.
Related
- Autophagy-lysosome pathway dysfunction in MASLD progression: molecular mechanisms and therapeutic targets.
- Endocrine resistance in HR+/HER2− breast cancer: molecular mechanisms and emerging therapeutic strategies
- Natural products in insomnia: Molecular mechanisms, action targets, and therapeutic potential
- Transendothelial Transport of Low-Density Lipoproteins in Atherosclerosis: Mechanisms of Activation and Possible Therapeutic Targets
- Liver Injury Repair and Regeneration: Molecular Mechanisms and Therapeutic Targets
BibTeX
@article{chaturvedi2026endocrine,
title = {{Endocrine determinants of MASLD: mechanisms and therapeutic targets.}},
author = {Richa Chaturvedi and Anu Mathew and Aprajita Pradhan and Monika Goyal and Monika Sharma and Varsha Kachroo and Chhavi Agrawal and Aishwarya Krishnamurthy and Surabhi Atreja and Ashish Atreja},
journal = {Frontiers in endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1967494},
url = {https://europepmc.org/article/MED/42898736},
note = {CC BY},
}
RIS
TY - JOUR
TI - Endocrine determinants of MASLD: mechanisms and therapeutic targets.
AU - Richa Chaturvedi
AU - Anu Mathew
AU - Aprajita Pradhan
AU - Monika Goyal
AU - Monika Sharma
AU - Varsha Kachroo
AU - Chhavi Agrawal
AU - Aishwarya Krishnamurthy
AU - Surabhi Atreja
AU - Ashish Atreja
PY - 2026
DA - 2026/10/05
JO - Frontiers in endocrinology
DO - 10.3389/fendo.2026.1967494
UR - https://europepmc.org/article/MED/42898736
AB - Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 30% of adults worldwide, yet is still framed largely as a hepatological disorder despite being driven substantially by endocrine and metabolic dysfunction. This review proposes a unified endocrine framework organised around seven hormonal axes, presenting each in terms of molecular pathogenesis, clinical presentation, and therapeutic implications. Insulin resistance is the central driver, coupling chronic caloric excess to hepatic de novo lipogenesis through selective hepatic insulin resistance, although genetic variants in PNPLA3 and TM6SF2 can uncouple steatosis from metabolic risk. Adipose tissue dysfunction contributes through adipocyte senescence, adipokine imbalance, and inflammatory adipose-liver signalling. Reduced hepatic thyroid hormone sensitivity, even in euthyroid individuals, predicts steatosis and fibrosis and underpins the first approved liver-directed therapy. Gonadal steroids exert sexually dimorphic effects, with testosterone deficiency, menopausal oestrogen loss, and polycystic ovary syndrome representing distinct risk states. Glucocorticoid dysregulation is stage-dependent, shifting from enhanced hepatic cortisol clearance in steatosis to local amplification in steatohepatitis. The gut-liver-endocrine axis, encompassing incretin, bile acid, and fibroblast growth factor signalling, has proved the most therapeutically tractable. Reduced GH/IGF-1 signalling, whether from pituitary disease or obesity-induced functional suppression, promotes both steatosis and fibrogenesis. Biological sex and life-course influences spanning developmental programming and ageing further modify these determinants. Two agents, resmetirom and semaglutide, now have US FDA accelerated approval for noncirrhotic MASH with moderate-to-advanced fibrosis, supporting the principle that correcting axis-specific endocrine dysfunction can produce measurable hepatic benefit; however, both approvals are accelerated and await confirmatory outcome data, while others remain investigational. An endocrine framework offers both a coherent account of pathogenesis and a rational basis for biomarker-guided, phenotype-targeted therapy.
SN - 1664-2392
ER -